Paclitaxel copyright transfer

Samyang Holdings Genexol's domestic copyright is from Boryung to HK inno.N

The original Taxol is sold jointly by Boryung for the first time in 7 years

Taxol & Genexol

The domestic copyright of Paclitaxel anticancer drugs has shifted one after another.

 

Samyang Biopharmaceuticals' Genexol, the No.

 

1 item in the market, will be jointly sold by HK inno.N instead of Boryung.

 

Boryung will jointly sell BMS Taxol, the original product, for the first time in seven years instead of Genexol.

 

The annual sales of the two products are worth 21 billion won for Genexol and 9 billion won for Taxol.

 

According to the pharmaceutical industry on the 16th, Boryung will jointly sell BMS Taxol in Korea from January 1 this year.

 

Taxol is a cytotoxic anticancer drug composed of Paclitaxel.

 

It is widely used for various cancers such as ovarian cancer, breast cancer, lung cancer, and gastric cancer.

 

It has been nearly 30 years since it was approved in Korea in 1996, but it is still widely used.

 

According to IQVIA, a pharmaceutical market research firm, Taxol's sales in 2021 are 9 billion won.

 

In the case of last year, it generated 5.8 billion won in sales by the third quarter.

 

Boryung is associated with Taxol.

 

BMS and Taxol have been jointly sold for eight years from 2008 to 2015.

 

The joint sales contract will bring Boryeong back to its original products for the first time in seven years.

 

Boryung co-sold its rival Genexol until just before.

 

Boryung jointly sold Samyang Biopharmaceuticals Genexol for six years from 2016 to last year.

 

Since 2018, the second year after Boryung took charge of sales, Genexol has risen to the top market share of the Paclitaxel ingredient.

 

Since then, Genexol has steadily maintained its No.

 

1 sales in the Paclitaxel market.

 

In 2021, Genexol's sales were 21.7 billion won.

 

Last year, it recorded cumulative sales of 16.5 billion won in the third quarter.

 

From Boryung's point of view, there is a situation in which they have to compete with the products they have grown to be the No.

 

1 in the market.

 

HKinno.N was in charge of Genexol, which Boryung was selling.

 

HKinno.N and Samyang Biopharmaceuticals recently signed a joint sales contract for domestic sales and marketing.

 

At higher general hospitals in Seoul and the metropolitan area, the two companies are jointly in charge of sales and marketing, while HKinno.N is in charge of other areas.

 

HKinno.N also has a deep connection with Genexol.

 

Samyang Holdings co-sold the product for 13 years from 2001 to 2013, when it developed Genexol with Paclitaxel Generics.

 

The joint sales deal reunited the two companies for the first time in 10 years.

 

For HKinno.N, the key is how solid Genexol's market share is.

 

As Boryeong has recently put a strong drive into the anticancer drug business, a fierce competition is expected in this market.

 

HKinno.N has CalmTOP, Aloxy, and Akynzeo in the anticancer field.

 

Through this Genexol partnership, HKinno.N plans to further increase its status in the anticancer drug market and actively expand its pipeline.

 

Kwak Dal-won, CEO of HKinno.N, said, "Just as the two companies have collaborated for a long time and made good results, we expect this Genexol to lead to positive results." Lee Young-Joon, CEO of Samyang Holdings, said, "HKinno.N has been selling Genexol for more than 10 years, so it has a high understanding of the product and has a professional anti-cancer drug sales organization." "We will firmly maintain our No.

 

1 position in the domestic market through a partnership with HKinno.N," he stressed.